ATE446761T1 - Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind - Google Patents
Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sindInfo
- Publication number
- ATE446761T1 ATE446761T1 AT03727670T AT03727670T ATE446761T1 AT E446761 T1 ATE446761 T1 AT E446761T1 AT 03727670 T AT03727670 T AT 03727670T AT 03727670 T AT03727670 T AT 03727670T AT E446761 T1 ATE446761 T1 AT E446761T1
- Authority
- AT
- Austria
- Prior art keywords
- reactive protein
- prevention
- treatment
- tissue damage
- ligands
- Prior art date
Links
- 108010074051 C-Reactive Protein Proteins 0.000 title abstract 5
- 102100032752 C-reactive protein Human genes 0.000 title abstract 5
- 230000002265 prevention Effects 0.000 title 1
- 230000000451 tissue damage Effects 0.000 title 1
- 231100000827 tissue damage Toxicity 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 7
- 108010045517 Serum Amyloid P-Component Proteins 0.000 abstract 2
- 102100036202 Serum amyloid P-component Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0211136.7A GB0211136D0 (en) | 2002-05-15 | 2002-05-15 | Treatment and prevention of tissue damage |
| PCT/GB2003/002096 WO2003097104A1 (en) | 2002-05-15 | 2003-05-14 | Treatment and prevention of tissue damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE446761T1 true ATE446761T1 (de) | 2009-11-15 |
Family
ID=9936726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03727670T ATE446761T1 (de) | 2002-05-15 | 2003-05-14 | Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7615543B2 (de) |
| EP (1) | EP1503800B1 (de) |
| JP (2) | JP2005531559A (de) |
| AT (1) | ATE446761T1 (de) |
| AU (1) | AU2003234000B8 (de) |
| CA (1) | CA2485852C (de) |
| DE (1) | DE60329839D1 (de) |
| DK (1) | DK1503800T3 (de) |
| ES (1) | ES2333522T3 (de) |
| GB (1) | GB0211136D0 (de) |
| WO (1) | WO2003097104A1 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211136D0 (en) * | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
| EP2392562B1 (de) | 2002-07-29 | 2018-03-07 | Cardax Pharma, Inc. | Strukturelle Carotenoidanaloge zur Hemmung und Abschwächung einer Erkrankung |
| US7763256B2 (en) | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
| US8012472B2 (en) | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
| ATE422943T1 (de) | 2002-12-23 | 2009-03-15 | William Marsh Rice Univeristy | Verfahren und verbindungen zur verstärkung der fybrozyten-bildung |
| GB0313386D0 (en) * | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| US20070265196A1 (en) * | 2004-01-21 | 2007-11-15 | Medvet Science Pty., Ltd. | Method of Modulating Pro-Inflammatory and Inflammatory Activity Mediated by C-Reactive Protein |
| EP1582527A1 (de) * | 2004-03-31 | 2005-10-05 | Ciba SC Holding AG | Synthese von phosphorbasierenden Liganden |
| EP1893227A2 (de) | 2005-06-06 | 2008-03-05 | Girish J. Kotwal | Verfahren zur behandlung oder prophylaxe von atherosklerose und reperfusionsschäden |
| CA2708004C (en) | 2006-12-04 | 2015-12-01 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
| US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| US8497243B2 (en) | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| DK2405929T3 (en) | 2009-03-11 | 2018-08-27 | Promedior Inc | SAP polypeptide for use in the treatment of autoimmune disorders and graft-versus-host disease |
| CA2754961C (en) | 2009-03-11 | 2018-04-10 | Promedior, Inc. | Treatment and diagnostic methods for hypersensitive disorders |
| UA110323C2 (en) | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| JP5822826B2 (ja) | 2009-06-17 | 2015-11-24 | プロメディオール， インコーポレイテッド | Ｓａｐ変異体及びその使用 |
| CN102725345B (zh) | 2009-09-18 | 2014-12-10 | 陶氏环球技术有限责任公司 | 用于凝塑成形工艺的粉末热塑性聚烯烃弹性体组合物 |
| US8674022B2 (en) | 2010-06-08 | 2014-03-18 | Dow Global Technologies Llc | Polyolefin elastomer composition for artificial leather applications |
| EP2790690A4 (de) * | 2011-12-14 | 2015-08-12 | Texas A & M Univ Sys | Zusammensetzungen und verfahren zur verwaltung neutrophiler bewegungen unter verwendung des serum-amyloids p (sap) |
| EP2890300B1 (de) | 2012-08-31 | 2019-01-02 | Kenji Suzuki | Überwachtes maschinenlernverfahren zur verringerung der strahlungsmenge in einer computertomografischen bildgebung |
| EP2957563A1 (de) * | 2014-06-19 | 2015-12-23 | Pentracor GmbH | Trennmaterial mit Phosphorylcholinderivaten |
| GB202002299D0 (en) * | 2020-02-19 | 2020-04-01 | Pentraxin Therapeutics Ltd | Agents for use in the treatment of tissue damage |
| WO2021197371A1 (zh) * | 2020-03-31 | 2021-10-07 | 南京金斯瑞生物科技有限公司 | 一种含有刚性连接子的生物偶联物 |
| WO2022178594A1 (en) * | 2021-02-25 | 2022-09-01 | Baker Heart and Diabetes Institute | C-reactive protein inhibitors |
| GB202111866D0 (en) | 2021-08-18 | 2021-09-29 | Ucl Business Plc | Prodrugs for use in the treatment of tissue damage |
| KR20230060368A (ko) * | 2021-10-27 | 2023-05-04 | 솔브레인 주식회사 | 환형 포스핀 화합물의 제조방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4640913A (en) | 1983-01-10 | 1987-02-03 | American Cyanamid Company | Phosphocholine derivatives having antihypertensive action |
| IL84252A (en) | 1987-10-23 | 1994-02-27 | Yissum Res Dev Co | Phospholipase inhibiting compositions |
| US5811568A (en) | 1992-10-08 | 1998-09-22 | Shaman Pharmaceuticals, Inc. | Process for the preparation of mono- and bis(phosphocholine) derivatives which have antifungal activity |
| US5681829A (en) | 1992-10-08 | 1997-10-28 | Shaman Pharmaceuticals, Inc. | Class of phosphocholine derivatives having antifungal activity |
| JP4524846B2 (ja) | 2000-04-20 | 2010-08-18 | 日油株式会社 | 化粧料 |
| US6764826B2 (en) | 2000-06-08 | 2004-07-20 | Board Of Regents, The University Of Texas System | Inhibitors of C-reactive protein induced inflammation |
| US7390795B2 (en) * | 2000-12-18 | 2008-06-24 | Pentraxin Therapeutics Limited | Treatment and prevention of tissue damage |
| EP1418905B1 (de) | 2001-08-08 | 2007-05-02 | Pentraxin Therapeutics Limited | Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma |
| GB0211136D0 (en) * | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
-
2002
- 2002-05-15 GB GBGB0211136.7A patent/GB0211136D0/en not_active Ceased
-
2003
- 2003-05-14 DE DE60329839T patent/DE60329839D1/de not_active Expired - Lifetime
- 2003-05-14 AT AT03727670T patent/ATE446761T1/de not_active IP Right Cessation
- 2003-05-14 ES ES03727670T patent/ES2333522T3/es not_active Expired - Lifetime
- 2003-05-14 JP JP2004505099A patent/JP2005531559A/ja not_active Ceased
- 2003-05-14 CA CA2485852A patent/CA2485852C/en not_active Expired - Fee Related
- 2003-05-14 WO PCT/GB2003/002096 patent/WO2003097104A1/en not_active Ceased
- 2003-05-14 AU AU2003234000A patent/AU2003234000B8/en not_active Ceased
- 2003-05-14 US US10/514,127 patent/US7615543B2/en not_active Expired - Fee Related
- 2003-05-14 EP EP03727670A patent/EP1503800B1/de not_active Expired - Lifetime
- 2003-05-14 DK DK03727670.6T patent/DK1503800T3/da active
-
2010
- 2010-02-04 JP JP2010022669A patent/JP2010174013A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2485852C (en) | 2012-01-17 |
| ES2333522T3 (es) | 2010-02-23 |
| EP1503800B1 (de) | 2009-10-28 |
| US7615543B2 (en) | 2009-11-10 |
| CA2485852A1 (en) | 2003-11-27 |
| AU2003234000B8 (en) | 2008-07-31 |
| DE60329839D1 (de) | 2009-12-10 |
| AU2003234000A1 (en) | 2003-12-02 |
| GB0211136D0 (en) | 2002-06-26 |
| EP1503800A1 (de) | 2005-02-09 |
| AU2003234000B2 (en) | 2008-06-05 |
| DK1503800T3 (da) | 2010-02-01 |
| WO2003097104A1 (en) | 2003-11-27 |
| JP2005531559A (ja) | 2005-10-20 |
| US20060019930A1 (en) | 2006-01-26 |
| JP2010174013A (ja) | 2010-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60329839D1 (de) | Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind | |
| IL311603B1 (en) | Bispecific antibodies and compounds containing them for cancer treatment | |
| EA200801172A1 (ru) | Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения | |
| EP1079859A4 (de) | Bifunktionelle moleküle sowie darauf basierende therapien. | |
| EA200801521A1 (ru) | Лиганды, которые обладают специфичностью связывания к vegf и/или egfr, и способы их применения | |
| EA200602044A1 (ru) | Молекулярно впечатанные полимеры, селективные по отношению к нитрозаминам, и способы их применения | |
| NO20062087L (no) | Bispesifikt antistoff som substituerer for funksjonelle proteiner | |
| WO2006020060A3 (en) | Iap binding compounds | |
| EA200200105A1 (ru) | СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ; | |
| EA201001734A1 (ru) | Улучшенные связывающие молекулы на основе фибронектина и их применение | |
| WO2005028624A3 (en) | Molecular scaffolds for kinase ligand development | |
| WO2002083854A3 (en) | Antibodies to vla-1 | |
| EP2221317A3 (de) | Pegylierte Single-domain-Antikörper (dAb) | |
| ATE40555T1 (de) | Verfahren zur organischen synthese von oligosacchariden,welche galactosamin- und uronsaeure-motive umfassen, oligosaccharide und ihre biologischen verwendungen. | |
| DE69942565D1 (de) | Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten | |
| ATE414718T1 (de) | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften | |
| DE60310400D1 (de) | Botulinustoxine zur behandlung von priapismus | |
| ATE417605T1 (de) | Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität | |
| WO2003071269A3 (en) | Methods and apparatuses for characterizing stability of biological molecules | |
| EA200602047A1 (ru) | Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака | |
| EP2335737A3 (de) | Künstliche Blutplättchen | |
| WO2006129843A3 (en) | Bispecific capturing molecule | |
| ATE317126T1 (de) | Liganden für den nachweis von prionen | |
| DE69837824D1 (de) | Löslicher Natamycin-Proteinkomplex | |
| WO2004069860A3 (en) | Isg15-conjugated proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |